SENSEX
NIFTY
GOLD
USD/INR

Weather

image 13    C

Company News

Livemint News

Company / Livemint

details

Emcure pushes into obesity segment with Poviztra, priced at 2,200 weekly

Despite an impending patent cliff in 2026 that will invite generic competition from companies like Sun Pharma and Dr. Reddy's, Emcures leadership believes the innovator edge and a robust metabolic portfolio will secure long-term market dominance.

22 Dec 2025 6:07 pm